We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Respiratory

Respiratory

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD
Cardiologycardiovascular riskCOPD

A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD

By MedXY|May 11, 2026

COPD exacerbations significantly increase cardiovascular risk for months. This article examines the link between COPD and heart disease, emphasizing proactive screening during flare-ups and evidence-based prevention strategies to improve su

In-hospital influenza vaccination is associated with reduced 1-year mortality in critical patients with chronic pulmonary disease: a real world target trial emulation
Critical Carechronic pulmonary diseasecritical care mortality

In-hospital influenza vaccination is associated with reduced 1-year mortality in critical patients with chronic pulmonary disease: a real world target trial emulation

By MedXY|May 9, 2026

In critically ill chronic pulmonary disease patients, receiving influenza vaccination during hospitalization reduces 1-year mortality by 12%, lowers 90-day mortality by 12%, decreases readmission risk by 13%, and reduces emergency visits by

Continuous Subphenotype Probabilities Expose High-Risk Patients Hidden Within “Hypoinflammatory” Acute Respiratory Failure
Critical CareAcute Hypoxemic Respiratory FailureARDS subphenotypes

Continuous Subphenotype Probabilities Expose High-Risk Patients Hidden Within “Hypoinflammatory” Acute Respiratory Failure

By MedXY|May 5, 2026

AHRF patients classified as hypoinflammatory are not prognostically uniform. Continuous biomarker-based probabilities reveal substantial mortality heterogeneity, especially below the binary 0.5 threshold, with implications for enrichment st

Pulmonary Arterial Hypertension Therapy Preserves Gas Exchange Overall in Portopulmonary Hypertension, but New Intrapulmonary Vascular Dilatations Can Emerge
Cardiologygas exchangehepatopulmonary syndrome

Pulmonary Arterial Hypertension Therapy Preserves Gas Exchange Overall in Portopulmonary Hypertension, but New Intrapulmonary Vascular Dilatations Can Emerge

By MedXY|May 4, 2026

In PoPH, PAH-specific therapy did not worsen oxygenation overall, although responses varied widely. Hemodynamic changes influenced gas exchange, and some patients developed new intrapulmonary vascular dilatations during follow-up.

Mild and Single Moderate COPD Exacerbations Predict Future Risks: Insights from a Community-Based Cohort Study
Internal MedicineCOPDexacerbations

Mild and Single Moderate COPD Exacerbations Predict Future Risks: Insights from a Community-Based Cohort Study

By MedXY|Apr 27, 2026

Community-based COPD patients with mild or single moderate exacerbations show higher future exacerbation risks and lung structural abnormalities, despite stable lung function decline rates.

Proximal Hypoglossal Nerve Stimulation Shows Promise for Moderate-to-Severe OSA in Landmark OSPREY Trial
NeurologyHypoglossal Nerve StimulationOSPREY Study

Proximal Hypoglossal Nerve Stimulation Shows Promise for Moderate-to-Severe OSA in Landmark OSPREY Trial

By MedXY|Apr 24, 2026

A recent randomized controlled trial demonstrates that proximal hypoglossal nerve stimulation significantly improves obstructive sleep apnea symptoms in patients intolerant to positive airway pressure therapy.

Once-Daily Umeclidinium-Vilanterol Outperforms Other LAMA-LABA Combinations in Reducing COPD Exacerbations
newsbronchodilator therapyCOPD

Once-Daily Umeclidinium-Vilanterol Outperforms Other LAMA-LABA Combinations in Reducing COPD Exacerbations

By MedXY|Apr 13, 2026

A large observational study finds that once-daily umeclidinium-vilanterol dry powder inhaler significantly reduces COPD exacerbation risk compared to glycopyrrolate-formoterol and tiotropium-olodaterol, while maintaining similar safety prof

Blood Eosinophil Count at COPD Exacerbation Predicts Long-Term Cardiovascular Risk: A Retrospective Cohort Study
Cardiologybiomarkercardiovascular events

Blood Eosinophil Count at COPD Exacerbation Predicts Long-Term Cardiovascular Risk: A Retrospective Cohort Study

By MedXY|Apr 11, 2026

A large retrospective cohort study of 143,517 patients reveals that non-eosinophilic acute exacerbations of COPD carry a significantly higher one-year risk of major adverse cardiovascular events compared with eosinophilic exacerbations, sug

Optimizing Positive End-Expiratory Pressure in Patients Without ARDS: From Non-Inferiority to Bayesian Probabilities of Benefit
Clinical Updatescritical caremechanical ventilation

Optimizing Positive End-Expiratory Pressure in Patients Without ARDS: From Non-Inferiority to Bayesian Probabilities of Benefit

By MedXY|Apr 5, 2026

Bayesian re-analysis of the RELAx trial suggests a 75-78% probability that a lower PEEP strategy is superior to higher PEEP in ICU patients without ARDS, with even higher benefits observed in specific clinical subgroups.

Mortality Trends in Mechanically Ventilated ARDS: 20 Years of Paradox Revealed
Critical CareARDSICD Coding

Mortality Trends in Mechanically Ventilated ARDS: 20 Years of Paradox Revealed

By MedXY|Apr 2, 2026

A landmark 20-year analysis of over 200,000 mechanically ventilated ARDS patients reveals a striking paradox—mortality declined during the ICD-9 era but increased after ICD-10 adoption, challenging assumptions about ARDS outcomes and highli

Nerandomilast in Idiopathic Pulmonary Fibrosis: Long-Term Insights from the FIBRONEER-IPF Trial
Internal MedicineChất Ức Chế PDE4BFIBRONEER-IPF

Nerandomilast in Idiopathic Pulmonary Fibrosis: Long-Term Insights from the FIBRONEER-IPF Trial

By MedXY|Mar 31, 2026

An in-depth analysis of the FIBRONEER-IPF trial’s extended follow-up data, evaluating the efficacy and safety of the PDE4B inhibitor nerandomilast in reducing clinical events and mortality in patients with idiopathic pulmonary fibrosi

Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up
Internal MedicineFIBRONEER-IPFIdiopathic Pulmonary Fibrosis

Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up

By MedXY|Mar 28, 2026

Long-term data from the FIBRONEER-IPF trial indicates that while nerandomilast did not significantly impact composite respiratory events, the 18 mg dose suggests a numerical reduction in mortality and maintains a favorable safety profile fo

Optimizing Influenza Protection in the Aging Diabetic Population: Evidence from the DANFLU-2 High-Dose Vaccine Trial
Clinical UpdatesDiabetes Mellitusgeriatrics

Optimizing Influenza Protection in the Aging Diabetic Population: Evidence from the DANFLU-2 High-Dose Vaccine Trial

By MedXY|Mar 28, 2026

This secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines provide superior protection against cardiorespiratory and cardiovascular hospitalizations in older adults with diabetes, particularly those with a

Post-Transplant Cyclophosphamide as a Potent Strategy for Bronchiolitis Obliterans Syndrome Prevention: A Comprehensive Clinical Synthesis
Clinical UpdatesBOScGvHD

Post-Transplant Cyclophosphamide as a Potent Strategy for Bronchiolitis Obliterans Syndrome Prevention: A Comprehensive Clinical Synthesis

By MedXY|Mar 28, 2026

This review evaluates the role of post-transplant cyclophosphamide (PTCy) in reducing the risk of bronchiolitis obliterans syndrome (BOS), highlighting recent multicenter data that demonstrates a 75% risk reduction mediated by the preventio

Distinct Biological Pathways Drive Restrictive and Obstructive Post-Tuberculosis Lung Disease: Insights from a Kenyan Cohort
Infectious Diseasesinfectious diseasesPost-Tuberculosis Lung Disease

Distinct Biological Pathways Drive Restrictive and Obstructive Post-Tuberculosis Lung Disease: Insights from a Kenyan Cohort

By MedXY|Mar 24, 2026

A prospective Kenyan cohort study identifies that post-tuberculosis lung disease (PTLD) affects 50% of survivors, driven by divergent transcriptomic signatures: early pro-fibrotic inflammation in restrictive phenotypes and persistent interf

In-Lab vs. At-Home Sleep Studies: Determining Minimum Recording Time and the Role of Positional Sleep Apnea
newsAHIHSAT

In-Lab vs. At-Home Sleep Studies: Determining Minimum Recording Time and the Role of Positional Sleep Apnea

By MedXY|Mar 23, 2026

This study compares in-lab and home sleep tests, revealing that in-lab polysomnography requires at least 6 hours of recording for accuracy, while home tests need only 3 hours, particularly due to the variables introduced by positional obstr

Beyond One-Size-Fits-All: Histologic Subtyping Redefines the Value of Lymph Node Dissection in Early Lung Adenocarcinoma
newsHistologic SubtypingLymph Node Dissection

Beyond One-Size-Fits-All: Histologic Subtyping Redefines the Value of Lymph Node Dissection in Early Lung Adenocarcinoma

By MedXY|Mar 21, 2026

A large-scale multicenter study reveals that guideline-adherent lymph node dissection provides a survival benefit only for patients with high-grade lung adenocarcinoma, suggesting that surgical extent should be tailored to histologic subtyp

Insulin Resistance and Hyperinsulinemia: The Hidden Drivers of Lung Function Decline in Diabetes
Diabetes & EndocrinologydiabetesFEV1

Insulin Resistance and Hyperinsulinemia: The Hidden Drivers of Lung Function Decline in Diabetes

By MedXY|Mar 20, 2026

A comprehensive study combining the German Diabetes Study data and Mendelian randomization establishes a causal link between insulin resistance and reduced lung function (FEV1 and FVC), positioning the lung as a critical target for metaboli

The Human Cost of Respiratory Care: Why Multidisciplinary Teams Cannot Shield Physicians from Burnout
newsBurnoutcystic fibrosis

The Human Cost of Respiratory Care: Why Multidisciplinary Teams Cannot Shield Physicians from Burnout

By MedXY|Mar 19, 2026

A comprehensive study of 569 cystic fibrosis professionals identifies physicians as the group most vulnerable to burnout, emotional exhaustion, and depersonalization. The research highlights administrative burden as a primary driver and cal

Predicting Post-Discharge Survival: The Long-term Pneumonia Mortality Index (L-PMI) Sets a New Standard for CAP Prognosis
Infectious Diseasescommunity-acquired pneumoniaL-PMI

Predicting Post-Discharge Survival: The Long-term Pneumonia Mortality Index (L-PMI) Sets a New Standard for CAP Prognosis

By MedXY|Mar 19, 2026

Researchers have developed and validated the Long-term Pneumonia Mortality Index (L-PMI), a clinical tool that accurately predicts mortality up to one year following hospital discharge for community-acquired pneumonia, including COVID-19 ca

Prev
7 / 16
1…56789…16
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles